Allergic rhinitis (AR) is a common medical condition in children. It is associated with significant morbidity because symptoms can adversely affect quality of life. The goals of treatment of AR are to provide effective prevention as well as symptom alleviation. Pharmacotherapy is often necessary for the reduction of symptoms and the associated morbidity. Intranasal steroids (INS) are highly effective drugs for treatment of AR and are more efficacious compared to other medications used to treat AR such as antihistamines and leukot-riene modifiers. Several formulations of INS are available, all of which have approximately the same efficacy and safety profile. The most common adverse effect is local irritation. Systemic absorption from nasal mucosa is low and thus systemic effects are rare. However, prolonged use of INS, especially in patients who are also using oral or inhaled steroids, can result in hypothalamic-pituitary-axis suppression. [Pediatr Ann. 2019;48(1):e43-e48.].